November 16, 2014 | The Israeli clinical stage pharmaceutical company that develops drugs to treat nervous system disorders, NeuroDerm, raised $45 million in a NASDAQ IPO. This is down from estimates assessing that NeuroDerm would raise between $60-82 million in the IPO. However, NeuroDerm began selling his 4,500,000 shares at $10.00 a share. Jefferies LLC and Cowen and Company are the book-running managers for the offering, along with Oppenheimer & Co. and Roth Capital Partners. NeuroDerm has its headquarters in Rehovot, Israel.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments